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ABSTRACT
Purpose. To assess the impact of perioperative blood
transfusion on overall and disease-free survival in patients
undergoing curative resection for cholangiocarcinoma.
Methods. In a single-center study, 128 patients undergo-
ing curative resection for cholangiocarcinoma between
2001 and 2010 were assessed. The median follow-up per-
iod was 19 months. Transfused and nontransfused patients
were compared by Cox regression and propensity score
analyses.
Results. Overall, 38 patients (29.7 %) received blood
transfusions. The patient characteristics were highly biased
with respect to receiving transfusions (propensity score
0.69 ± 0.22 vs. 0.11 ± 0.16, p \ 0.001). In the unadjusted
analysis, blood transfusion was associated with a 105 %
increased risk of mortality [hazard ratio (HR) 2.05, 95 %
CI 1.19–3.51, p = 0.010]. In the multivariate (HR 1.14,
95 % CI 0.52–2.48, p = 0.745) and the propensity score-
adjusted Cox regression (HR 1.02, 95 % CI 0.39–2.62,
p = 0.974), blood transfusion had no influence on overall
survival. Similarly, in the propensity score-adjusted Cox
regression (HR 0.62, 95 % CI 0.24–1.58, p = 0.295), no
relevant effect of blood transfusion on disease-free survival
was observed.
Conclusions. To our knowledge, this is the first propensity
score-based analysis providing compelling evidence that
the worse oncological outcome after curative resection for
advanced cholangiocarcinoma in patients receiving
perioperative blood transfusions is caused by the clinical
circumstances requiring the transfusions, not by the blood
transfusions themselves.
Cholangiocarcinoma accounts for 3 % of gastrointesti-
nal tumors and is the second most common primary hepatic
malignancy, representing 10–25 % of primary hepatic
malignancies worldwide.1–3 Curative treatment is usually
limited to localized cholangiocarcinomas and requires
surgical removal by liver resection or pancreaticoduoden-
ectomy.4,5 These major resections are associated with a
perioperative morbidity of 31–85 % and mortality between
5 and 10 %.6–8 Such complex and invasive procedures
often require perioperative blood transfusions despite the
potential detrimental side effects. There is evidence that
allogeneic blood transfusion has an immunosuppressive
effect associated with an increased risk of tumor recurrence
and poor prognosis.9,10 However, it has remained unclear
whether the worse outcomes in patients receiving blood
transfusions are directly caused by the transfusions them-
selves or are rather a consequence of poor prognostic
factors associated with blood transfusions, such as peri-
operative anemia, the complexity of the procedure,
advanced tumor stage, age, comorbidities, and the occur-
rence of (infectious) complications. The latter hypothesis is
supported by a recent Cochrane Review of blood transfu-
sions that could not identify a causal relationship in more
than 12,000 colorectal cancer patients.11 Nevertheless, only
a few reports regarding the association between perioper-
ative blood transfusion and the outcomes of
cholangiocarcinoma patients are available, and these
studies did not apply the appropriate statistical methods to
distinguish between direct effects and the circumstances
that lead to the poor outcomes after transfusion.12,13
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This single-center study of curatively resected cholan-
giocarcinoma patients who received or did not receive
blood transfusions was designed to investigate the impact
of perioperative blood transfusion on survival and recur-
rence. To assess the putative causal relationship between
blood transfusion and worse oncologic outcomes, both Cox
proportional hazard regression analyses and propensity
score methods were applied.
PATIENTS AND METHODS
The present retrospective study was based on the pro-
spectively maintained cholangiocarcinoma database of the
University Hospital Heidelberg. Between November 2001
and July 2010, a total of 240 consecutive patients with
histologically proven cholangiocarcinoma underwent sur-
gical exploration. Seventy-six patients underwent palliative
resection (biliodigestive anastomosis and/or a gastroenter-
ostomy) in locally not resectable tumors or in presence of
distant metastases and six patients who underwent only
resection of the extrahepatic biliary tract were excluded. A
total of 17 stage IVa cholangiocarcinoma patients were
also excluded. In-hospital mortality occurred in 13 of 158
patients (8.2, 95 % CI 4.9–13.6); these patients were also
excluded from further analysis. Eight of them received
blood transfusions. Finally, 128 patients with curative
resection (R0; clear surgical margins) remained for further
analyses; 38 received blood transfusions, and 90 did not.
The patients were divided into two groups according to
whether they received perioperative allogeneic blood
transfusions between the third preoperative day and the
seventh postoperative day.
Data Collection and Definitions
Data on patient demographics, comorbidities, operative
details, morbidity, postoperative mortality, and histological
results were obtained from medical charts. The TNM
classification was based on the fifth edition of the inter-
national union against cancer.14 Patients were followed-up
regularly at outpatient clinics or the National Center of
Tumor Diseases (NCT). Clinical follow-up visits including
tumor marker measurements were performed every
3 months during the first 3 years and thereafter every
6 months until the fifth year. As a baseline examination an
abdominal computed tomography was performed 3 months
postoperatively or upon suspected recurrence.
Overall survival was defined as the duration from the
operation until death due to any cause. Disease-free survival
was defined as the duration from the operation until the date
of cholangiocarcinoma recurrence. All patients were regu-
larly followed in an outpatient clinic, or the patient’s primary
physician was personally contacted. During the entire study
period, only prestored leukocyte-depleted allogeneic blood
was transfused (one unit = 300 ml). All resections were
performed or supervised by experienced hepatobiliary sur-
geons and were performed using highly standardized
procedures, as described previously.15,16 Hepatic mono- and
bisegmentectomies were defined as minor liver resections.
Resection and reconstruction of a potentially infiltrated
vessel was only performed unresectable tumors (R0; clear
surgical margins).
Statistical Analyses
Statistical analyses were performed by R statistical
software (www.r-project.org). Two-sided p values of\0.05
were considered statistically significant. Continuous data
were expressed as the mean ± standard deviation or the
median and interquartile range (IQR) as appropriate. For
comparing proportions, Chi square statistics were used, and
for comparing continuous variables, t tests were used.
Missing data for intraoperative blood loss (n = 2) and
tumor size (n = 22) were imputed using the random sur-
vival forest method.17 First, the risk for receiving a blood
transfusion was assessed on the basis of age, gender,
American Society of Anesthesiologists (ASA) classifica-
tion, preoperative hemoglobin, type of operation, UICC
tumor stage, tumor size, tumor localization, vascular
resections, and intraoperative blood loss using logistic
regression and a backward variable selection procedure
based on Akaike’s information criterion. The same covar-
iates, including blood transfusion, were then assessed as
putative prognostic factors for overall and disease-free
survival in unadjusted and risk-adjusted Cox regressions
including a backward variable selection procedure from the
full Cox regression model based on Akaike’s information
criterion. The proportional hazard assumption was tested
using scaled Schoenfeld residuals and inspection of the
hazard ratio (HR) plots. No violations of the assumption of
proportional hazards were observed.18 Moreover, a pro-
pensity score analysis, which is a superior and more refined
statistical method for adjusting for potential baseline con-
founding variables, was performed.19 The ‘‘MatchIt’’ and
‘‘optmatch’’ R packages were used to perform a bipartite
weighting propensity score analysis.20 The distance mea-
sure was estimated by logistic regression using the risk set
described above to predict blood transfusion. Patients who
received blood transfusions and did not have a counterpart
with respect to the distance measure among the patients
who did not receive blood transfusions and vice versa were
excluded from the analysis. Thereafter, the distance mea-
sure was reestimated. Otherwise, the default settings were
left unchanged. The baseline risk profiles of the matched
patients were compared to ensure that no major differences
in the baseline patient characteristics persisted. The
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prognostic value of blood transfusion for overall survival
was finally assessed in a Cox regression model by applying
the weights obtained by the propensity score analysis and
by stratifying for the subclasses from the propensity score
analysis.
To examine a potential dose-dependent association
between blood transfusion, overall and disease-free sur-
vival the number of blood transfusions was considered as a
continuous variable and assessed in unadjusted and risk-
adjusted Cox regressions including a backward variable
selection procedure. Additionally, a propensity score
matching was performed as described above comparing
patients who received two or more blood transfusions with
patients who received no or one blood transfusions. Finally,
another sensitivity analysis was performed including the
patients who died during the hospital stay and stage IVa
cholangiocarcinoma patients in the analysis.
A power analysis for the unadjusted Cox regression
analysis revealed a power of 66 % for a two-sided 5 %
type-I error to detect a HR of 2.05 for the risk of mortality.
A similar power analysis which included only the 74
patients included in the propensity score analysis with 57
and 17 in each group revealed a power of 40 %.21
RESULTS
Patient Characteristics and Blood Transfusions
A total of 128 eligible patients were identified, with a
median follow-up time of 19 months (range
1.4–94 months). Of these patients, 38 (29.7 %) received
blood transfusions. Six patients (4.7 %) received one blood
unit, 13 patients (10.2 %) received two blood units, one
patient (0.8 %) received three blood units, three patients
(2.3 %) received four blood units, and 15 patients (11.7 %)
received five or more blood units (with a maximum of 11
units). A total of 156 blood units were transfused: 77
during the operation and 79 postoperatively. Table 1
summarizes the patient characteristics and the periopera-
tive outcomes. Of note, total pancreatectomy was
performed in six patients as a result of a resulting small
pancreatic remnant and obvious pancreatitis (n = 5), or as
a result of necrosis of the remnant pancreas (n = 1). In a
total of 16 patients (13 %) vascular resection and recon-
struction was performed. This included the resection of the
portal vein (n = 14), inferior vena cava (n = 1), and the
right hepatic artery (n = 1).
Risk for Blood Transfusion
In the univariate analysis, various patient characteristics
and short-term outcomes differed significantly between
patients receiving blood transfusions and those who did not
(Table 1). After the multivariate adjustment, older age, a
more advanced UICC tumor stage, and greater intraoper-
ative blood loss were statistically significant independent
predictors for receiving blood transfusions (Table 2).
The propensity score for transfused patients was
0.688 ± 0.216, compared with 0.111 ± 0.159 in non-
transfused patients (p \ 0.001), thus indicating a strong
bias regarding most patient characteristics between the two
groups. When performing the propensity score matching
procedure, 54 patients had to be excluded (21 transfused
patients and 33 nontransfused patients) because they could
not be matched with patients from the other group (Fig. 1).
Hence, 74 patients were included in the propensity score-
based analysis. After the matching procedure, the propen-
sity score was nearly the same in the matched groups
(0.413 ± 0.207 vs. 0.416 ± 0.216, p = 0.953). Figure 1
displays the change in the distribution of the propensity
score due to the matching procedure. After propensity
score matching, no significant differences in the patient
characteristics were found between patients receiving
blood transfusions and those who did not. The study pop-
ulation obtained by the matching procedure is depicted in
Table 2.
Blood Transfusion as a Prognostic Factor for Overall
Survival
An unadjusted Cox proportional hazards regression
analysis revealed that blood transfusion was a statistically
significant prognostic factor and was associated with an
approximately 105 % greater risk of overall mortality (HR
of death 2.05, 95 % CI 1.19–3.51, p = 0.010) (Table 3).
The 3-year overall survival for patients receiving blood
transfusions was 34 % (95 % CI 20–56), compared with
62 % (95 % CI 50–76) for patients who were not trans-
fused (Fig. 2, left). After adjusting for a variety of
potential confounding factors in risk-adjusted Cox
regression analyses, blood transfusion had a small non-
significant effect on the risk of death in the full model (HR
1.14, 95 % CI 0.52–2.48, p = 0.745) and blood transfu-
sion was not selected as an independent prognostic factor
in a backward variable selection procedure. After adjust-
ing the data according to the propensity score analysis,
blood transfusion was confirmed to have no effect on the
risk of death (HR 1.02, 95 % CI 0.39–2.62, p = 0.974).
After propensity score adjustment, the 3-year survival for
transfused patients was 25.9 % (95 % CI 10.0–66.9),
compared with 31.4 % (95 % CI 19.7–349.9) for non-
transfused patients with comparable Kaplan–Meier curves
(Fig. 2, right).
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Disease-free Survival
Unadjusted Cox proportional hazards regression analysis
revealed that blood transfusion was a statistically significant
prognostic factor for disease-free survival (HR 1.59, 95 % CI
1.00–2.51, p = 0.049). After risk adjustment in the multi-
variate Cox regression analysis (HR 0.80, 95 % CI
0.41–1.59, p = 0.526) or the propensity score analysis (HR
0.62, 95 % CI 0.24–1.58, p = 0.295), blood transfusion was
no longer a prognostic factor for disease-free survival.
Sensitivity Analyses
To analyze a potential dose-dependent association
between blood transfusion and survival blood transfusions
were treated as a numerical variable. In unadjusted Cox
regression, the number of blood transfusions significantly
impaired overall survival (HR 1.09, 95 % CI 1.00–1.19,
p = 0.042) and as a tendency impaired the disease free
survival (HR 1.06, 95 % CI 0.98–1.14, p = 0.150). In
multivariable analysis, the number of blood transfusions
did not significantly influence overall survival (HR 0.99,
95 % CI 0.87–1.11, p = 0.822) or disease free survival
(HR 0.94, 95 % CI 0.84–1.04, p = 0.216). In none of the
analyses, the number of blood transfusions was selected as
an independent prognostic factor. An additional propensity
score matched analysis compared patients receiving two or
more blood transfusions (n = 32) against patients receiv-
ing one or no blood transfusion (n = 96). After exclusion
of 70 patients, 12 patients with two or more blood
TABLE 1 Patient characteristics and outcome
Characteristic Variable Total Transfusion No transfusion p
(n = 128) (n = 38) (n = 90)
Follow-up (mo) 22.9 ± 19.0 23.7 ± 16.2 22.6 ± 20.2 0.732a
Age (y) 63.5 ± 10.7 66.4 ± 9.2 62.2 ± 11.1 0.032a
Gender Male 85 (66.4 %) 23 (60.5 %) 62 (68.9 %) 0.360b
Female 43 (33.6 %) 15 (39.5 %) 28 (31.1 %)
ASA stage II 78 (60.9 %) 20 (52.6 %) 58 (64.4 %) 0.211b
III 50 (39.1 %) 18 (47.4 %) 32 (35.6 %)
Preoperative hemoglobin (g/l) 129.3 ± 14.7 124.6 ± 15.4 131.2 ± 14.1 0.026a
Tumor localization Intrahepatic 30 (23.4 %) 9 (23.7 %) 21 (23.3 %) 0.006b
Central/hilar 37 (28.9 %) 18 (47.4 %) 19 (21.1 %)
Distal 61 (47.7 %) 11 (28.9 %) 50 (55.6 %)
UICC stage I 22 (17.2 %) 3 (7.9 %) 19 (21.1 %) 0.006b
II 87 (68.0 %) 24 (63.2 %) 63 (70.0 %)
III 19 (14.8 %) 11 (28.9 %) 8 (8.9 %)
Tumor size (cm) 3.5 ± 2.8 4.0 ± 3.1 3.3 ± 2.6 0.234a
Operation (Extended) right hemihepatectomy 30 (23.4 %) 14 (36.8 %) 16 (17.8 %) 0.002b
(Extended) left hemihepatectomy 30 (23.4 %) 10 (26.3 %) 20 (22.2 %)
Minor liver resection 7 (5.5 %) 3 (7.9 %) 4 (4.4 %)
Whipple procedure 55 (43.0 %) 7 (18.4 %) 48 (53.3 %)
Total pancreatectomy 6 (4.7 %) 4 (10.5 %) 2 (2.2 %)
Vascular resection No 112 (87.5 %) 29 (76.3 %) 83 (92.2 %) 0.013b
Yes 16 (12.5 %) 9 (23.7 %) 7 (7.8 %)
Intraoperative blood loss 100 ml 10.7 ± 7.5 16.7 ± 8.7 8.1 ± 5.2 \0.001a
Length of hospital stay (d) 21.9 ± 16.0 30.6 ± 19.9 18.2 ± 12.4 0.001a
Dindo grade 0 45 (35.2 %) 4 (10.5 %) 41 (45.6 %) \0.001b
I 22 (17.2 %) 5 (13.2 %) 17 (18.9 %)
II 33 (25.8 %) 19 (50.0 %) 14 (15.6 %)
III 25 (19.5 %) 8 (21.1 %) 17 (18.9 %)
IV 3 (2.3 %) 2 (5.3 %) 1 (1.1 %)
Values are presented as n (%) or mean ± standard deviation
ASA American Society of Anesthesiologists, UICC International Union Against Cancer
a t test
b Chi square test
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transfusions and 46 patients with one or no blood trans-
fusions remained in the analysis. The propensity scores
were nearly the same in these two matched groups
(0.354 ± 0.151 vs. 0.344 ± 0.135, p = 0.822). In this
analysis, overall survival (HR 1.08, 95 % CI 0.38–3.02,
p = 0.888) and disease free survival (HR 0.86, 95 % CI
0.31–2.39, p = 0.773) were not influenced by blood
transfusions.
Another sensitivity analysis was performed including
the 13 patients who died during the hospital stay and the 17
stage IVa cholangiocarcinoma patients. After propensity
score matching, blood transfusion did not influence overall
survival (HR 0.72, 95 % CI 0.37–1.42, p = 0.336) or
disease-free survival (HR 0.93, 95 % CI 0.50–1.73,
p = 0.817) confirming the results.
DISCUSSION
To date, only a few reports have focused on the impact
of blood transfusion on outcome after resection for chol-
angiocarcinoma.12,13 This study is the first to use
propensity score methods to assess this issue in patients
undergoing curative resection for cholangiocarcinoma,
with an ultimate goal of differentiating between the direct
effects of transfusion and the effects of confounding fac-
tors. Perioperative blood transfusion was one of the
independent prognostic factors for overall survival in the
unadjusted analysis of the entire study group. After
adjustment, our results indicate that perioperative blood
transfusion does not influence overall or disease-free sur-
vival in cholangiocarcinoma patients. These results were
obtained using both multivariate Cox regression and pro-
pensity score-adjusted analyses. Thus, the negative
association between blood transfusion and oncological
outcome is likely not associated with blood transfusion
itself but rather with the clinical circumstances necessi-
tating the transfusion.
However, even though blood transfusion did not
decrease survival in the present investigation, the avoid-
ance of unnecessary blood transfusions is of cardinal
importance for various reasons. In addition to the costs, the
possible negative sequelae of blood transfusion are well
known, including alloimmunization, the transmission of
viral diseases, graft-versus-host disease, and an increased
postoperative infection rate.22–26
In the present study, 38 of the 128 patients (29.7 %)
were transfused during or after resection. Our transfusion
rate compares favorably with those found by others, with
reported blood transfusion requirements of 10–53 %.8,27
Blood transfusion was associated with a 105 % increased
risk of mortality in the unadjusted analyses. However, as a
result of the marked differences in various prognostic
factors between the transfused and nontransfused patients,
this association was merely coincidental. To further adjust
for unobserved variables, mixed-effects Cox regression
modeling was applied.28 In the risk-adjusted analyses,
blood transfusion did not remain an independent predictor
of overall survival. Therefore, the increased risk observed
in the unadjusted analysis is due to differences in the
baseline characteristics and not to blood transfusion itself.
The same conflicting findings were also obtained for other
malignancies with respect to disease-free survival. Several
authors have demonstrated that the time to recurrence is
shorter in patients who receive blood transfusions.29–32
Other authors, however, have not been able to identify any
adverse relationship between blood transfusion and the
recurrence of cancer. Regarding autologous and allogeneic
blood transfusion, a randomized trial by Busch et al. that
included 475 colorectal cancer patients did not find that
autologous blood transfusion improved the prognosis in
colorectal cancer patients compared with allogeneic blood
transfusion. The authors concluded that the circumstances
necessitating blood transfusions are the real predictors of
prognosis and not the blood transfusions.33
Improvements in surgical techniques, anesthetic proto-
cols, and medical management have significantly improved
outcomes for patients undergoing liver and pancreatic
cancer surgery, with acceptable morbidity and mortal-
ity.6,15,34,35 Nevertheless, these procedures, especially
extended hepatectomies, are frequently accompanied by
Distribution of Propensity Scores
Unmatched treatment units
Matched treatment units
Matched control units
Unmatched control units
1.00.0
Propensity score
0.80.60.40.2
FIG. 1 Distribution of the propensity scores. Each circle represents
one patient. The distributions of the propensity scores for patients
with and without blood transfusions (treatment units and control
units) who could be matched are shown. The propensity scores for
patients who could not be matched because their characteristics could
not be matched with those of patients from the other group are also
shown. The sizes of the circles for matched patients without blood
transfusions (control units) represent the weights obtained by the
propensity score matching procedure
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substantial blood loss, and many patients require allogeneic
blood transfusions during either the operation or the post-
operative period.35–37 The indications for blood transfusion
are obviously determined by numerous factors, such as the
amount of blood lost during surgery, the extent of the
surgical procedure, and the skill of the surgeon. Many
experimental and clinical studies have demonstrated that
blood transfusion may have an adverse effect on postop-
erative outcomes after surgery for various malignant
neoplasms because of the induction of posttransfusion
immunosuppression.38–42 Using a multivariate analysis,
Gozzetti et al. 43 studied 522 patients undergoing elective
liver resections for benign and malignant liver diseases and
observed a significant correlation between blood transfu-
sion and long-term survival in patients with metastatic
tumors and HCC. According to our results, blood transfu-
sion is a surrogate marker for higher-risk patients and does
not impact disease-free or overall survival. Previous pro-
spective randomized trials were designed to compare
allogeneic, autologous, and leukocyte-depleted blood
transfusions.33,44,45 These trials demonstrated that autolo-
gous and leukocyte-depleted blood transfusions do not
result in better outcomes than allogeneic transfusions for
patients with colorectal cancer.46
This study has several limitations. First, this was a ret-
rospective and not a randomized controlled study including
a rather small number of patients receiving blood transfu-
sion. However, it is nearly impossible and ethically
questionable to perform a randomized trial to study this
association. Second, this analysis included a mixture of
intrahepatic, hilar, and distal cholangiocarcinoma. This
heterogeneity and possible changes of the surgical and
perioperative management over time, might have intro-
duced a relevant bias. Third, the exclusion of patients in the
propensity score-matched analysis resulted in further
decrease of an already small sample size and therefore in
a relevant loss of statistical power.47 Additionally, a
cutoff effect for the amount of blood transfusions can
not be excluded. Despite these limitations, the adverse
effect of blood transfusion disappeared after risk
adjustment for both overall and disease-free survival.
Fourth, as a result of the propensity score methodology,
the results are partly based on advanced cholangiocar-
cinoma patients with a poor oncologic outcome. This
poor outcome might have hidden a potential negative
prognostic impact of blood transfusions. Finally, as a
result of normal physiological ageing and metabolic
processes there is leaching of biologically active sub-
stances from the cells into stored blood products. These
substances have immunomodulatory effects promoting
cell growth and angiogenesis and may therefore have a
direct effect on tumor growth.48 In the present study, we
could not control for a possible negative effect of blood
storage duration on the oncological outcome.
In summary, blood transfusion in patients after curative
resection for advanced cholangiocarcinoma is not associ-
ated with worse overall and disease-free survival after risk
adjustment in multivariate Cox proportional and propensity
score analyses, irrespective of the possible immunosup-
pressive effects of allogeneic blood transfusion. Blood
transfusion merely serves as a surrogate parameter for
other poor prognostic factors. Therefore, the administration
of autologous blood transfusions does not seem to influence
the oncologic results. Still, the avoidance of unnecessary
blood transfusions remains of cardinal importance as a
result of the other possible negative sequelae of blood
transfusion.
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score-adjusted analyses.
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